Patterns of progression in non-IPF fibrotic interstitial lung disease

Usual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift?

(2023) Moisés Selman et al.   Lancet Respiratory Medicine

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2022) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

(2022) Nathan Hambly et al.   EUROPEAN RESPIRATORY JOURNAL

Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse

(2022) Kerri A Johannson et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Progressive Pulmonary Fibrosis: Should the Timelines be Taken Out of the Definition?

(2022) Vincent Cottin et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Validation of Proposed Criteria for Progressive Pulmonary Fibrosis

(2022) Janelle Vu Pugashetti et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reply to: Functional criteria to define progressive pulmonary fibrosis: Searching for the Holy Grail

(2022) Janelle Vu Pugashetti et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

(2021) Jürgen Behr et al.   Lancet Respiratory Medicine

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease

(2021) Toby M. Maher et al.   EUROPEAN RESPIRATORY JOURNAL

Lung function trajectory in progressive fibrosing interstitial lung disease

(2021) Justin M. Oldham et al.   EUROPEAN RESPIRATORY JOURNAL

Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting

(2021) Sebastiano Emanuele Torrisi et al.   Frontiers in Pharmacology

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

(2020) Athol U Wells et al.   Lancet Respiratory Medicine

The natural history of progressive fibrosing interstitial lung diseases

(2020) K.K. Brown et al.   EUROPEAN RESPIRATORY JOURNAL

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS® study)

(2020) Mouhamad Nasser et al.   EUROPEAN RESPIRATORY JOURNAL

Spectrum of Fibrotic Lung Diseases

(2020) Marlies Wijsenbeek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

(2020) Peter M George et al.   Lancet Respiratory Medicine

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

(2019) Toby M Maher et al.   Lancet Respiratory Medicine

What's in a name? That which we call IPF, by any other name would act the same

(2018) Athol U. Wells et al.   EUROPEAN RESPIRATORY JOURNAL